Anda di halaman 1dari 9

Untitled Document

David Eric Adson, M.D.


Curriculum Vitae Office Address: MAPS Applied Research Center 7450 France Avenue South, Suite 265 Edina, MN 55345 952-937-9000 www.mapsresearch.com Undergraduate Education: 1971-1974
The Colorado College
University of Minnesota, College of Biological Sciences
B.S. in Biology, Summa Cum Laude Postgraduate Training and Medical Residency: 1976-1980
University of Minnesota, Minneapolis, School of Medicine

M.D., Alpha Omega Alpha 1980-1981
Intern in Department of Surgery, Emory University Affiliated Hospitals,

Atlanta, Georgia 1982-1983
Department of Orthopedic Surgery, Emory University, Atlanta, Georgia 1993-1996
Department of Psychiatry, University of Minnesota Academic/Professional Appointments: 1984-1988

Clinical Assistant Professor of Family Practice, University of Minnesota,


Minneapolis, Minnesota 1996-1998
Instructor in Psychiatry, University of Minnesota,

Minneapolis, Minnesota 1998- present
Assistant Professor, University of Minnesota, Department of Psychiatry,

Minneapolis, Minnesota 1999-present
Clinical Assistant Professor, University of Minnesota,

Department of Pharmacology, Minneapolis, Minnesota 2004-2009

Associate Professor, University of Minnesota, Department of Psychiatry 2009-present


Adjunct Associate Professor, U of MN Department of Psychiatry Certification and Licensure: American Board of Medical Examiners Board Certified in Psychiatry: Certificate #49096 State of Minnesota; #27588 State of Georgia; #22706, not active U.S. DEA certification #AA1097989 Employment: 1981-1982

Emergency Department Physician, Crawford Long Memorial Hospital,


Atlanta, Georgia

Adson CV.htm[10/14/2013 10:39:22 AM]

Untitled Document
1983-1984
Emergency Department Physician at Eitel Hospital and Golden Valley

Medical Center, Minneapolis, Minnesota 1984-1988 Family Practice; Tyrol Medical Clinic, Golden Valley, Minnesota 1987-1992
Consultant to M-T (Med. Tech.) Venture Capital Group, Minneapolis, Minnesota 1988
Wayzata Family Practice, Wayzata, Minnesota 1989-1993
Staff Physician, Phalen Clinic, Columbia Heights, Minnesota
1993-1996
Resident Physician in Psychiatry, Minneapolis, Minnesota 1997-ongoing
Have served, or am currently serving on the speakers bureau for Astra
Zeneca, Bristol Myers Squibb, Glaxo Smith Kline, Forest Labs, Organon,

and Pfizer pharmaceuticals 1999-2001


Psychiatric Consultant, Fairview Northland Clinic, Princeton, Minnesota 2001-ongoing Psychiatric Consultant, Family Life Center, Coon Rapids, Minnesota 2006-2008
Clinical Lead Minnesota Department of Human Services - Medicaid

Mental Health Pharmacy Management Project 2009-ongoing


Principal Investigator, MAPS Applied Research Center, Edina, Minnesota Honoraries and Professional Societies: Alpha Omega Alpha; The Honor Medical Society American Psychiatric Association American Association for the Advancement of Science The International Society of Affective Disorders Society of Biological Psychiatry Ad Hoc Review for: The Annals of Pharmacotherapy The Journal of Psychopharmacology The Journal of Laboratory and Clinical Medicine CNS Drugs: Adis Drug Profile Committee and Administrative Service: 1994-2005
Member, IRB (Institutional Review Board); Human Subjects Committee,

University of Minnesota 1997-2009 Member, Residency Training Committee 1998

Interim Chair, Human Subjects Committee, Panel 4 1998-2005


Chair, Human Subjects Committee, Panel 5 1999

Member of Search Committee, College of Pharmacy, for Assistant

Adson CV.htm[10/14/2013 10:39:22 AM]

Untitled Document

Professor of Clinical Psychopharmacology 1999-2008


Member AHC Conflict Review and Management Committee 1999-2007
Vice-Chair, Department of Psychiatry Research Committee 1999-2007
Member, Department of Psychiatry Research Council 1999-2000
Member, Chemical Abuse and Recovery Evaluation (CARE) Advisory

Committee established by the Corrections Commissioner to

evaluate chemical dependency programming within the

Minnesota Department of Corrections Autumn, 2002 Member, Mental Health Task Force (working with Minnesota Council of

Health Plans). Task force commissioned by the Attorney General 2002-present


Director, Ambulatory Research Center, University of MN

Department of Psychiatry Instructional Experience: Full time clinical duties include: Supervision and training of 3rd and 4th year medical students, PharmD students, and psychiatry residents PGY1-4. 1996-1997 AdPy 5121 (College of Physical Therapy); "Somatoform and
Dissociative Disorders, Eating Disorders" 1996- present Since initial appointment to faculty:
inpatient service for two years; transition to outpatient clinic for several years; appointment to
consult liaison service; currently with mix of outpatient clinic and consult liaison service 1996-present AdPy 5500 (Medical School) "Psychopharmacology"; provide overview of

psychopharmacology to 3rd and 4th year medical students during their

6 week psychiatry rotation 1997-present AdPy 5500 (Medical School) "Clinical Application of Antidepressants"

(as above, for 3rd and 4th year medical students) 1998-1999 AdPy 5121 (Medical School); "Dementia and Delirium, Somatoform

Disorders" 1999-present Course Committee Member, Year 2 Psyche Course: Psychopathology I,

Physiological Treatments I: "Treatment and diagnosis of psychotic



disorders other than schizophrenia" 2003
Psychopathology III, Winter 2003 (residents): "Psychological Factors
Affecting Medical Conditions" 2006-present Psychopharmacology Course for G3s; Kis of SGAs and ADs, review of
MAOIs, rating scales in clinical practice Peer- Reviewed Publications: McLaughlin
EG, McLaughlin DJ & Adson DE: Developmental anatomy of a dimitic basidiomycete, Pterula sp.; Canadian Journal of Botany; 56,3: 288-296, 1978 Data collection and manuscript preparation Adson DE, Mitchell JE & Trenkner S.: The superior mesenteric artery syndrome and gastric dilatation in eating disorders: a report of two cases and a review of the literature; International Journal of Eating Disorders; 21:103-114, 1997 Mitchell JE, Maki DD, Adson DE, Ruskin BS, & Crow S: The selectivity of inclusion and exclusion criteria in
bulimia nervosa treatment studies. International Journal of Eating Disorders; 22:243-252, 1997 Adson DE, Mitchell JE & Crow S: Spontaneous pneumothorax in anorexia nervosa; a case report. Psychosomatics, 39,2: 162-164, 1998

Adson CV.htm[10/14/2013 10:39:22 AM]

Untitled Document

Adson DE, Crow SJ, Meller WH, & Magraw, RM: Potential drug-drug interactions on a
tertiary-care hospital consult liaison psychiatry service.
Psychosomatics, 39, 4: 360-5 1998 Kim SW, Grant JE, & Adson DE: Double-Blind Naltrexone and Placebo Comparison Study in the Treatment of Pathological Gambling. Biological Psychiatry, 49: 11,
2001 Kim SW, Grant JE, Adson DE, & Remmel R: A Possible Naltrexone and Nonsteroidal Analgesics Interaction. Journal of Clinical Psychopharmacology, 21: 632-634, 2001 Data collection, revision of manuscript Adson DE & Kotlyar M: A Probable Interaction Between an Oral Contraceptive and the Antidepressant Nefazodone: A Case Report. Journal of Clinical Psychopharmacology,
21,:618-619, 2001 Adson DE, Erickson-Birkedahl SL, & Kotlyar M: Case Report; An Unusual Presentation of Sertraline and Trazodone Overdose. The Annals of Pharmacotherapy, 35: 1375-1377, 2001 Kim SW, Grant JE, Adson DE, Shin YC,& Zaninelli R: A double-blind, placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling disorder.
Journal of Clinical Psychiatry, 63,6: 501-507, 2002 Adson
DE & Kotlyar M: Premature Ejaculation Associated With Citalopram Withdrawal. The Annals of Pharmacotherapy, 37: 1804-1806, 2003
Literature review and manuscript preparation Adson DE, Kushner MG, Eiben KM, & Schulz C: Preliminary Experience with Adjunctive Quetiapine in Patients on Selective Serotonin Reuptake
Inhibitors. Depression and Anxiety, 19: 121-126, 2004 Kotlyar M,
Brauer L, Tracy TS, Hatsukami DK, Harris J, Bronars CA, Adson DA.
Inhibition of CYP2D6 activity by bupropion. Journal of Clinical
Psychopharmacology, 25:225-29, 2005 Adson, DE, Kushner MG, Fahnhorst TA: Treatment of Residual Anxiety Symptoms with Adjunctive Aripiprazole in Depressed Patients Taking Selective Serotonin Reuptake Inhibitors. Journal of Affective Disorders, 86: 99-104, 2005 Kotlyar
M, Dysken M, Adson DE. Update on drug-induced depression in the elderly. Am J Geriatr Pharmacother, 4(1):288-300, March 2006. Kotlyar
M, Brauer LH, al'Absi M, Adson DE, Robiner W, Thuras P; Harris J, Finocchi ME; Bronars CA, Candell S, Hatsukami DK. Effect of bupropion on
physiological measures of stress in smokers during nicotine withdrawal.
Pharmacol Biochem Behav, 2006; 83:370-379. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB. D-Cycloserine augmented exposure therapy for
obsessive-compulsive disorder. Biological Psychiatry 2007 Oct 15;62(8):835-8 . Pardo JV, Sheikh SA, Kuskowski MA, Surerus-Johnson C, Hagen MC, Lee JT, Rittberg BR, Adson DE. Weight
loss during chronic, cervical vagus nerve stimulation in depressed patients with obesity: an observation. International Journal
of Obesity, June 12, 2007, 1-4. Von Ruden AE, Adson DE, Kotlyar M, Effect of selective serotonin reuptake inhibitors on cardiovascular morbidity and mortality. J Cardiovasc Pharmacol Ther. Mar 2008 13(1):32-40. Kotlyar M, Donahue C, Thuras P, Kushner MG, O'Gorman
N, Smith FA, Adson DE. Physiological response to a speech stressor presented in a virtual reality environment. Psychophsiology, Sept 4, 2008. Pardo JV, Sheikh SA, Schwindt GC, Lee JT, Kuskowski MA, Surerus C, Lewis SM, Abuzzahab FS, Adson DE, Rittberg BR. Chronic vagus nerve stimulation for treatment-resistant depression decreases resting ventromedial prefrontal
glucose metabolism. Neuroimage, Aug. 15, 2008 42(2):879-89. Donahue
CB, Kushner MG, Thuras PD, Murphy TG, Van Demark JB, Adson DE. Effect of Quetiapine versus Placebo on Response to Two Virtual Public Speaking Exposures in Individuals with Social Phobia. Journal of Anxiety Disorders, 2009 Apr;23(3):362-8. Epub 2008 Dec 24 Bortnick
B, El-Khalili N, Banov M, Adson D, Datto C, Raines S, Earley W, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine xr) monotherapy in major depressive disorder: a placebo-controlled, randomized study. Submitted to Journal of Affective Disorders. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN. Aripiprazole augmentation in major depression: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS

Adson CV.htm[10/14/2013 10:39:22 AM]

Untitled Document
Spectrums, 2009 14(4): 197-206 Books and Book Chapters: Mitchell
JE, Pomeroy C & Adson DE: Managing medical complications of eating disorders (book chapter) Handbook of Psychotherapy of Eating Disorders; Garner D, Garfinkel P; Guilford Press NY, April 1997 Mitchell JE, Crosby R, Wonderlich S, & Adson DE: Elements of Clinical Psychiatric Research (Book); APA press; May 2000. Other Publications: Adson DE: Seasonal Affective Disorder; Minnesota Health Care News, October 2003 and Minnesota Physician Jan. 2004 Adson
DE: Considering Long-Term Outcome and Tolerability in the Treatment of Bipolar Disorder, Current Psychosis and Therapeutics Reports, 2:
121-127, 2004 Pardo JV, Sheikh SA, Schwindt G, Lee JT, Surerus-Johnson C, Pardo PJ, McCarten JR, Kushowski MA, Dysken MW, Abuzzahab F, Rittberg BR, Adson DE. Functional neuroimaging in treatment - resistant depression. Depression: Mind and Body, 2007;
3(2):57-70. Grants/Research: NIH/Foundation: Principal
Investigator (with Mitchell JE and Crow SJ); "Naltrexone in Binge Eating Disorder", March 1995-1997 $24,600 (Direct Cost) Dept. Funded Co-Investigator
(Crow SJ as PI); "Stepped Care vs. Best Available Care for Bulimia Nervosa", NIH RO1 grant, awarded 1999-ongoing $1,303,765 (Direct Cost) Co-Investigator
(with Kotlyar M); "Effect of Paroxetine on Physiological Response to Mental Stress" 2000-2003 $17,000 (Direct Cost) University of Minnesota Graduate School Co-Investigator (with Kotlyar M); "Paroxetine Effects on Cardiovascular Response to Mental Stress in Patients with Stable Angina"2001-ongoing $80,000 (Direct Cost) AHA Co-Investigator (with Kotlyar M, Hatsukami D); Effects of Desipramine and Nicotine Patch on Smoking Behavior" 2002 NIMH Co-Investigator
(with Kotlyar M, Kushner M, al'Absi M, Hatsukami D); "Effects of Zyban and Cognitive Behavioral Therapy on Stress Reactivity and Smoking Withdrawal Symptoms" 2001-ongoing $168,852 (Direct Cost) AHC/Fairview grant Co-Investigator (with Kotlyar M); Effect of Buproprion on the Cytochrome P450 Drug Metabolizing Enzyme MMF 2004-2006 Co-Investigator
(with Kushner, MG); "CBT Treatment of Anxiety Disorder in Comorbid Alcoholics. NIAAA. 9/05 - 8/31/2010 $1,250,000 (Direct). Co-Investigator (with Kushner, MG, Donahue, C); "D-Cycloserine Augmentation of Behavioral Therapy for Smoking Cessation"
2006-2008 MMF grant $14,000 Investigator initiated: Principal Investigator (with Clayton PJ); "Pilot Study of RemeronTM (mirtazapine) in Depressed Patients Greater than 70 Years of Age", February 1997 - October 1997 $29,800 (Direct Cost) Co-Investigator
(with Kim SW); "An Open Study of Naltrexone in the Treatment of Pathological Gambling Disorder", September 1997 - December 1997 Co-Investigator
(with Kim SW); "Double-Blind Study of Naltrexone and Placebo Treatment of Pathological Gambling Disorder", December 1997 November 1999 $46,412 (Direct Cost) Co-Investigator (with Kim SW, Grant JE); "A
16-Week, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Paroxetine in the Treatment of Pathological Gambling Disorder", March 2000 - 2001 $129,500 (Direct Cost) Co-Investigator (with Pardo JV, Sheikh S); Effect of Vagus Nerve Stimulation on Brain Metabolism in Depression, 2000-2003, Principal
Investigator (with Schulz SC, Kushner MG, Eiben KM); "Quetiapine as an Adjunctive Therapy for Persistent Anxiety in Those Receiving Treatment with an SSRI" 2001-2002 $27,850 (Direct Cost)

Adson CV.htm[10/14/2013 10:39:22 AM]

Untitled Document
Principal Investigator (with Brown E); "Aripiprazole as an Adjunctive Treatment for Persistent Anxiety in Those Receiving Treatment with an SSRI" 2003- $39,500 (direct cost). Principal
Investigator; _The use of Quetiapine in the Treatment of Social Phobia Effect on Cue Reactivity in Response to Virtual Reality Public Speaking Environment 08/30/06- 08/27/07, $113,000. Selected industry sponsored multi-center trials: Co-Investigator
(with Rittberg BR, Kim SW, Meller WH); "A Multicenter, Double-Blind, Placebo-Controlled, Flexible Dose Evaluation of the Safety and Efficacy of LAMICTAL (Lamotrigine) in the Treatment of Major Depressive Episode in Patients with Bipolar Disorder" (SCAA2110). September 1997 - July 1998 $125,000 (Direct Cost) Principal Investigator (with Clayton PJ, Rittberg BR) "An Open Label Evaluation of the Efficacy, Safety, and Dosing of Citalopram in Outpatients with Depression" (CIT-MID #97-06-000) July 1998 - September 1998 $20,600 (Direct Cost) Principal
Investigator (with Rittberg BR, Hermann SA, Sheikh SA); "Olanzapine Plus Fluoxetine Combination Therapy in Treatment-Resistant
Depression: A Dose Ranging Study", December 1999 -2001 $175,000 (Direct Cost) Co-Investigator (with Rittberg BR) "A Multicenter, Pivotal, Safety and Efficacy Study of the NeuroCybernetic Prosthesis (NCP) System in Patients with Depression" Cyberonics, Inc. Protocol D-02; May 2000-ongoing $341,500 (Direct Cost) Co-Investigator
(with Rittberg BR, Hermann SA); "A Long Term Prospective, Multicenter Study to Compare the Clinical Quality of Life, and Health Care Utilization of the NCP System to the Standard of Care Treatment with Depression (Cyberonics D-04); May 2000-ongoing Principal Investigator (with Meller WH) "A Randomized, Double-Blind, Parallel Group, Placebo Controlled Study Evaluating the Efficacy and Safety of Three Doses of SB-659746-A (5 mg, 10 mg, and 20 mg/day) Versus Placebo in Patients with Major Depressive Disorder" SB-659746-A/002, September 2001- June 2003 $94,000 (Direct Cost) Principal Investigator (with Meller WH) "An Double-Blind Study of the Safety and Efficacy of Lu
26-054 in Patients with Generalized Anxiety Disorder" Forest Laboratories Protocol SCT-MD-06; June 2001- May 2003 $79,000 (Direct Cost) Principal Investigator "An Open-Label Extension Study of the Safety and Efficacy of Lu 26-054 in Patients with Generalized Anxiety Disorder" Forest Laboratories Protocol SCT-MD-17; November 2001- May 2003 $20,700 (Direct Cost) Co-Investigator (with Willenbring M as PI) "A Phase III, Multi-Center, Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Medisorb Naltrexone in Alcohol Dependent Adults" ALK21-003, March 2002 -
present $142,000 (Direct Cost) Principal Investigator "A Multicenter, Double-Blind Randomized, Placebo-Controlled Comparison of the Effects on Sexual Functioning of ExtendedRelease Bupropion Hydrochloride (300-400mg) and Escitalopram (10-20mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period" January 2003 - Present $179,000 (Direct Cost) Principal
Investigator "A 7 Month, Multicenter, Parallel, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended-Release
Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Depressive Episodes in Subjects with a History of Seasonal Affective Disorder Followed by an 8 week Observational Follow-up Phase." October 2003-- Present $104,500 (Direct Cost) Principal Investigator; A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety of Aripiprazole as Adjunctive Therapy in the Therapy in the Treatment of Patients With Major Depressive Disorder May 2005-ongoing likely through 2006 $320,000 direct Principal
Investigator; A Multi-Center, Double-Blind, Randomized-Withdrawal, Parallel-Group, Placebo-Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period (Amethyst Study); April 2006-ongoing $215,420 direct Principal Investigator; A Mulit-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) as Monotherapy in the Treatment of Adult Patients with Major Depressive Disorder (Opal Study) May 2006-ongoing $101,000 direct Principal
Investigator; A 52 Week Randomized, Double Blind Placebo Controlled, Multicenter, Parallel Group Study of the Long Term Efficacy,
tolerability and Safety of Agomelatine 25 mg and 50 mg in the Prevention
of Relapse of Major Depressive Disorder (MDD) Following open label
treatment of 16-24 weeks. (Novartis Study), 01/01/07 - 03/31/2010,
$710,283.

Adson CV.htm[10/14/2013 10:39:22 AM]

Untitled Document
Selected Presentations: Summer 1993 Invited Lecturer; "The Sociology of Death" (Soc 5956) November 1993 Psychiatry Grand Rounds, VA medical center; "Suicide: an overview" Winter 1994 Invited lecturer; "The Sociology of AIDS" (Soc 5960) April 1994 Psychiatry Grand Rounds, University of MN, Case Presentation, Minneapolis, MN November 1994 Tuesday Morning Departmental conference; "Lithium and the Kidney" June 1995 Tuesday Noon Journal club; "Therapies for binge eating disorder" July 1996 Invited Lecturer "Sociology of Mental Illness" (Soc. 5150); history of psychopharmacology 1996
Eating disorders in China; panel discussant; "Culture and Prevalence of Eating Disorders", American Psychiatric Association Annual Meeting, New York, NY September 1996 Medical Resident's Noon Conference: "Anxiety Disorders" November 1997 "Mirtazapine Treatment in the Elderly", Remeron Expert Meeting, Charleston, SC October
1999 Invited Lecturer: "Current Issues in the Treatment of Depression". Update on Assessing Depression. Menninger Continuing Education, Bloomington, MN July 1999 Medical Resident's Noon Conference: "Treatment of Depression" February
2000 Grand Rounds Presentation: "How Are the Selective Serotonin Reuptake Inhibitors Different?" Altru Health System,
Grand Forks, ND February 2000 Grand Rounds Presentation: "An Unusual Case of Serotonin Syndrome" (faculty discussant for a case presented by Jill Nasby, MD), University of Minnesota, Minneapolis, MN July 2000 Grand Rounds Presentation: "Anxiety Disorders: An Overview". Department of Family Practice, Mayo Foundation, Rochester, MN October
2000 Annual Psychiatry Review (CME program): Mood Disorders: "Serotonin Syndrome and SSRIs", University of Minnesota, Minneapolis, MN March 2001 E.N.T. Residents evening lecture; "A Practical Approach to Treating Anxiety and Depression" August
2001 Philippine Minnesotan Medical Association (CME program): "Depression in the Medically Ill Patient" Two Harbors, MN December
2001 Fairview Pain Clinic Noon Conference: "Thoughts about Psychiatric Treatment of the Chronic Pain Patient", Minneapolis, MN December 2001 23rd Annual Cardiovascular Conference (Health Partners CME program): "Depression and Anxiety in the Medically Ill", St. Paul, MN, May
2002 Innovation, Inclusiveness, and Informed Consent "Inclusion of Special Populations in Research: Psychiatry Subjects" (oral presentation): Minneapolis, MN; (event hosted by U
of M IRB, and the OHRP) July 2002 Department of Surgery Transplant Conference. "Psychiatric Considerations in the Transplant Patient", University
of Minnesota, Department of Surgery October 2002 Grand Rounds Presentation: "Seroquel for Anxiety?" University of Minnesota, Department of Psychiatry January 2003 Grand Rounds Presentation: "Anxiety and Depression in Medical Illness." Fairview Southdale Hospital February
2003 Presentation to Neurology Dept. Morning conference: "Psychiatric Problems of Interest to Neurologists" March
2003 Grand Rounds Presentation: "Potential Drug-Drug
Interactions in Antidepressant Therapy". HCMC Dept. of Psychiatry

Adson CV.htm[10/14/2013 10:39:22 AM]

Untitled Document

April
2003 Presentation to Department of Medicine Noon Conference: "Impact of Mood and Anxiety Disorders in the Medically Ill",
University of MN June 2003 HealthEast CME program: "Pharmaceutical Approaches to Anxiety and Depression" September
2003 Boynton Health Center CME program: "Treatment of Anxiety and Depression: A Focus on Drug Interactions" November
2003 Investigator Sponsored Studies Consultants Meeting. "Quetiapine as an Adjunctive Therapy for Persistent Anxiety in Those Patients Receiving an SSRI, Aventura, FL September 2003 University of MN Dept. of Psychiatry 4th Annual CME Review: "Treatment of Depression with CoMorbid Anxiety Disorders October 2003 28th Annual MAPA Fall CME conference: "Impact of Depression and Anxiety on Medical Illness" February
2004 CME activity (sponsored by AstraZeneca): Treatment Advances in the Spectrum of Mood Disorders. ""Bipolar Affective Disorder; Prevalence and Diagnostic Issues", Bloomington, MN Sept.
19-20, 2005 Course director and moderator for 6th annual psychiatry review: "An Entertaining and Eclectic Elucidation of Psychiatric Erudition", Minneapolis, MN 2006 American Psychiatric Association Meeting Symposium: The Use of SGAs in depression and anxiety. Sept.
25-26, 2006 Course director and moderator for 7th annual psychiatry review: "The Impulsive-Compulsive Spectrum", Minneapolis, MN June 2007 Presentation to U of
M AHC Office of Clinical Research - LifeScience Alley Breakthrough Series. "Specific Disease Sates - Clinical Applications of Neuromodulation". Minneapolis, MN June 2007 Grand Rounds Presentation: "Case Presentation: Post Infectious Brain Disorder (PANDAS?)". The University of Minnesota Department of Psychiatry Selected Abstracts: Kim
SW, Grant JE, Adson DE, Shin YC, Toth JA: "A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Pathological Gambling Disorder" (oral presentation). New Research Program and Abstracts, 153rd Annual Meeting of the American Psychiatric Association,
Chicago, IL 2000 Kim SW, Grant JE, Shin YC, Toth JA, Adson DE, Zaninelli R: "A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Paroxetine in the Treatment of Pathological Gambling Disorder" (poster). New Research Program and Abstracts, 153rd Annual Meeting of the American Psychiatric Association, Chicago, IL 2000 Kim SW, Grant JE, Adson DE, Shin YC, Toth JA: "A Double-Blind, Placebo-Controlled Study
of Naltrexone in the Treatment of Pathological Gambling Disorder" (poster). New Research Program and Abstracts, Annual Meeting of the Society of Biological Psychiatry, Chicago, IL 2000 Adson DE, Schulz SC, Kushner MG, Eiben MA: "An Open Trial of Quetiapine for Anxiety in Patients Receiving an SSRI" (poster). New Research Program and Abstracts, Annual Meeting of the Society of Biological Psychiatry, Philadelphia, PA, 2002 Sheikh S, Adson DE, Rittberg B, Pardo JV:
"Metabolic Abnormalities in Treatment-Resistant Depression" (poster). New Research Program and Abstracts, Annual Meeting of the Society of Biological Psychiatry, Philadelphia, PA, 2002 Sheikh
S, M.D.; Hagen M, B.S.; Adson DE, M.D.; Rittberg B, M.D.; Abuzzahab FS Sr, M.D.; Ph.D.; Lee JT, M.S; Pardo JV, M.D; Ph.D.; Rush JA, M.D. "Chronic effects of VNS TherapyTM on Severe, Chronic Treatment-Resistant Depression" (poster) ACNP, Hawaii, December 2002 Sheikh
S, M.D.; Hagen M, B.S.; Adson DE, M.D.; Rittberg B, M.D.; Abuzzahab FS Sr, M.D.; Ph.D.; Lee JT, M.S; Pardo JV, M.D.; Ph.D. "Effects
of Vagus Nerve Stimulation on brain metabolism in Severe, Chronic Treatment-Resistant Depression: One year outcome" (poster) SOBP, San
Francisco, May 2003 Kotlyar M, Brauer L, Tracy TS, Hatsukami DK, Harris J, Bronars C, Adson DE. Effect of bupropion on cytochrome P450 2D6 (CYP2D6) activity (abstract). CPNP Annual Meeting, Chicago, IL, April 2004

Adson CV.htm[10/14/2013 10:39:22 AM]

Untitled Document
Kotlyar M, Brauer LH, al'Absi M, Adson DE, Robiner W, Thuras P; Harris J, Finocchi ME; Bronars CA, Candell S, Hatsukami DK. Effect of bupropion on physiological measures of stress in smokers during nicotine withdrawal (abstract). SRNT Annual Meeting, Orlando, FL (February 2006). Presented as Encore Presentation at CPNP Annual Meeting, Baltimore, MD (April 2006) El-Khalili
N, Banov M, Bortnick B, Adson D, Datto C, Raines S, Earley W, Brecher M . Efficacy and tolerability of extended release quetiapine
fumarate (Quetiapine XR) monotherapy in major depressive disorder (MDD):
a randomized, placebo-controlled clinical trial (Study 003). Presented
as poster at Society of Biological Society (May 2008) Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D,
Taylor L, Hazel J, Marcus RN. The third consecutive, positive, double-blind, placebo-controlled trial of apripiprazole augmentation in the treatment of major depression (Study CN138-165). Presented as poster at American College of Neuropsychoharmacology 47th Annual Meeting
(Dec. 2008)

Adson CV.htm[10/14/2013 10:39:22 AM]